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Marine environments are a fruitful source of bioactive compounds some of which are the
newest leading drugs in medicinal therapeutics. Of particular importance are organisms
like sponges and macroalgae and their associated microbiome. Planctomycetes,
abundant in macroalgae biofilms, are promising producers of bioactive compounds
since they share characteristics, like large genomes and complex life cycles, with
the most bioactive bacteria, the Actinobacteria. Furthermore, genome mining revealed
the presence of secondary metabolite pathway genes or clusters in 13 analyzed
Planctomycetes genomes. In order to assess the antimicrobial production of a large
and diverse collection of Planctomycetes isolated from macroalgae from the Portuguese
coast, molecular, and bioactivity assays were performed in 40 bacteria from several
taxa. Two genes commonly associated with the production of bioactive compounds,
nonribosomal peptide synthetases (NRPS), and polyketide synthases (PKS) genes were
screened. Molecular analysis revealed that 95% of the planctomycetes potentially have
one or both secondary bioactive genes; 85% amplified with PKS-I primers and 55%
with NRPS primers. Some of the amplified genes were confirmed to be involved in
secondary metabolite pathways. Using bioinformatic tools their biosynthetic pathways
were predicted. The secondary metabolite genomic potential of strains LF1, UC8, and
FC18 was assessed using in silico analysis of their genomes. Aqueous and organic
extracts of the Planctomycetes were evaluated for their antimicrobial activity against
an environmental Escherichia coli, E. coli ATCC 25922, Pseudomonas aeruginosa
ATCC 27853, Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC 6633, and
a clinical isolate of Candida albicans. The screening assays showed a high number of
planctomycetes with bioactive extracts revealing antifungal (43%) and antibacterial (54%)
activity againstC. albicans andB. subtilis, respectively. Bioactivity was observed in strains
from Rhodopirellula lusitana, R. rubra, R. baltica, Roseimaritima ulvae, and Planctomyces
brasiliensis. This study confirms the bioactive capacity of Planctomycetes to produce
antimicrobial compounds and encourages further studies envisaging molecule isolation
and characterization for the possible discovery of new drugs.
Keywords: planctomycetes, antibiotic activity, antifungal activity, PKS and NRPS genes, screening, secondary
metabolite, genome mining
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INTRODUCTION
Diseases like cancer and antibiotic resistance impose us a
pressing need for the discovery of new effective leads in their
treatment. Since the discovery of penicillin, the miracle drug of
the twentieth century by Fleming in 1928, we assisted to a boom
of molecules release with antibiotic capacity. Due to excessive
and incorrect use of antibiotics and the capacity of bacteria to
escape their action, we witnessed, in the last decade, to a dramatic
increase of bacterial pathogens presenting multidrug resistance
to antibacterial agents (Roca et al., 2015). The search for novel
bioactive molecules has been essentially based on terrestrial
organisms. However, in the last decades, attention has been paid
to marine samples. The unique characteristics of the marine
environment allied to its unexplored and unknown biologic
diversity makes the marine habitats a potential great source of
new bioactive molecules. Moreover, microorganisms, in their
adaptation to a multitude of different and sometimes extreme
marine conditions, are holders of a myriad of metabolic pathways
including secondary metabolite activity that are not found in
terrestrial ecosystems (Karabi et al., 2016). Furthermore, they are
easily and sustainably cultivated in large scale at a reasonable
cost which are good characteristics for technological exploitation
(Waites et al., 2001; Debbab et al., 2010).
Bioactive compounds, often produced as secondary
metabolites, can be, for example alkaloids, sugars, steroids,
terpenoids, peptides, and polyketides (Simmons et al.,
2005). These substances are mainly produced as a defense
strategy and can be used by man as antibacterial, antifungal,
antiviral, antitumor, and immunosuppressive among other
potential medicines (Laport et al., 2009). The production of
secondary metabolites involves complex molecular structures
and biochemical pathways (Hutchinson, 2003). Nonribosomal
peptides and polyketides are biocompounds synthesized by
two classes of enzymes: the nonribosomal peptides synthetases
(NRPS) and polyketide synthases (PKS), respectively (Grozdanov
and Hentschel, 2007). These enzymes are responsible for many
secondary metabolites that exhibit an important biological
activity and may be valuable drugs (Hutchinson, 2003; Ansari
et al., 2004; Kennedy et al., 2007). These pathway systems have
been studied and described mainly in Actinobacteria but are also
present in other bacterial taxa and even in filamentous fungi
and plants (Ayuso-Sacido and Genilloud, 2005). PKS and NRPS
genes are codified by gene clusters presents in the genome of
various groups of bacteria (Donadio et al., 2007; Graça et al.,
2013, 2015).
Planctomycetes are a bacterial phylum with very particular
features that make them good candidates for the production
of novel bioactive molecules. They possess complex life cycles
and quite large genomes for prokaryotes, characteristics that
are typical of bacteria known for their bioactive potential like
Streptomyces and Myxobacteria (Jeske et al., 2013). In their
adaptation to a wide range of habitats, including extreme
environments (Lage and Bondoso, 2014), planctomycetes
developed diversified metabolisms still unexploited. Other
characteristics make them unique. These include a complex
cell plan (Lage et al., 2013; Santarella-Mellwig et al., 2013),
polar budding of many members (Ward et al., 2006), and the
absence of the bacterial division protein FtsZ (Pilhofer et al.,
2008), the presence of membrane coat-like proteins (Santarella-
Mellwig et al., 2010), and endocytosis (Lonhienne et al., 2010).
Althoughmuch is still unknown about planctomycetes secondary
metabolism, some recent studies have recently pointed out their
bioactive potential. Donadio et al. (2007) analyzed the genome of
Rhodopirellula baltica SH1255 and verified the presence of two
small NRPSs, two monomodular PKSs, and a bimodular NRPS-
PKS which may be involved in the synthesis of five different,
unknown products. In Antarctic sediments, Zhao et al. (2008)
identified planctomycetal type I polyketide synthase domains.
Using a comprehensive genomemining approach for the analyses
of 13 genomes, Jeske et al. (2013) found 102 candidate genes or
clusters.
In our study, we explored the bioactive potential of a
unique collection of planctomycetes isolated from the biofilm
of macroalgae by genome mining, as well as PKS-I and NRPS
genemolecular analyses and antimicrobial bioactivity screenings.
As biofilms are complex highly dynamic structured ecosystems
where strong chemical competition occurs and planctomycetes
are relatively slow growing bacteria, these bacteria should
possess well-equipped chemical machinery to be able to fight
for their survival and impose themselves in such a competing
environment.
MATERIALS AND METHODS
Biological Material
The 40 planctomycetes under study, belonging to 10 taxa, were
isolated from macroalgae surfaces biofilms within the scope of
several diversity and phylogenetic studies carried out in rocky
beaches in north of Portugal (Lage and Bondoso, 2011). The
bacteria were maintained in pure culture at 25◦C in M600/M14
agar medium (Lage and Bondoso, 2011). The phylogenetic
relationship of the strains are shown in a phylogenetic tree
constructed using the sequences available in GenBank database.
The sequences of UC49.2 and FC9.2 were assigned with
the following accession numbers—KX495344–KX495345. The
sequences were aligned using clustalW, and a final maximum
likelihood (ML) phylogenetic tree was generated using the
aligned 1316 bp applying the general time reversible model
with gamma distributed with invariant sites (G+I) rates in
MEGA6.06.
The panel of target microorganisms used in the screening
assays were an environmental strain of E. coli (Cabral and
Marques, 2006), E. coli ATCC 25922, Pseudomonas aeruginosa
ATCC 27853, Staphylococcus aureus ATCC 25923, Bacillus
subtilis ATCC 6633, and a clinical isolate of C. albicans.
Amplification and Sequencing of PKS-I and
NRPS Genes
Total genomic DNA was extracted from pure cultures using
the E.Z.N.A. Bacterial DNA Isolation Kit (Omega), following
the recommended instructions. In order to perform the
screening of the genomic bioactive potential the degenerate
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primers MDPQQRf (5′-RTRGAYCCNCAGCAICG-3′) and
HGTGTr (5′-VGTNCCNGTGCCRTG-3′) and MTRF2 [5′-
GCNGG(C/T)GG(C/T)GCNTA(C/T)GTNCC-3′] and DKF
(5′-GTGCCGGTNCCRTGNGYYTC-3′) were used for the
amplification of PKS-I (Kim et al., 2005) and NRPS (Neilan
et al., 1999), respectively. These primers amplify for the alpha
keto syntethase of PKS-I and core motif-V of NRPS genes. The
amplification mixture was composed of 12.5 µL of NZYTaq 2 ×
Green Master Mix, 2 µL of each primer, 1 µL genomic DNA as
template, and completed with sterilized ultrapure water to a final
volume of 25 µL. The amplification parameters for both primers
were identical and the PCR amplifications were performed
in a MyCyclerTM Thermo Cycler (Bio-Rad) as described in
Graça et al. (2013). The PCR products were visualized after
electrophoresis in a 1.2% agarose gel with 1 × TAE buffer in a
VWR GenoPlex. The expected PCR products size of PKS-I and
NRPS genes were 750 and 1000 bp, respectively.
Bands with several sizes were excised and purified using
Illustra GFX PCR DNA and Gel Band Purification Kit
(GE Healthcare) and directly sequenced using appropriate
primers. The sequences were manually corrected and consensus
constructed by means of Vector NTI Advance 11.5.3. Data used
for UC8 PKS-I was the portion of the annotated genome that
matched with the amplicon sequenced, with additional 200 bp
above and after alignment, in order to retrieve more information
for the analysis.
In silico Analysis of PKS-I and NRPS Genes
The resulting consensus sequences of the strains were searched
through Basic Local Alignment Search Tool (BLAST), classified
in the Nucleotide collection of the National Center of
Biotechnology Information (NCBI) based on somewhat
similarity. Information regarding similarity and coverage values
was assessed for the validation of the amplification of the targeted
genes.
Natural Product Domain Seeker—NaPDoS, a bioinformatic
tool to search for PKS andNRPSmodules and to predict bioactive
pathway products, was used based on the FASTA file with the
nucleotide sequences choosing Predicted coding sequences or
PCR products. The sequences were screened to detect and extract
C- (NRPS) and KS- (PKS) domains and candidate secondary
metabolites domains (Ziemert et al., 2012).
Blast2go is a fast bioinformatics tool that uses several
public databases to assign a biological function to a sequence
by identifying similar characterized sequences. This tool was
used to compare and confirm results obtained by manual
search and NaPDoS. Gene synteny of the results obtained
in the prediction of the metabolite pathways were analyzed
in SynTax (Oberto, 2013). Nucleotide sequences of the genes
were translated into amino acidic sequences using ExPASy tool
and the longer sequences translated were used to construct
a phylogenetic tree. Phylogenetic and molecular evolutionary
analyses were conducted using MEGA version 6 (Tamura et al.,
2013). Sequences were aligned using clustalW, and a final ML
phylogenetic tree was generated applying Equal input model after
searching for the fittest model also inMEGA6.06. Sequences with
small size were removed from the analysis.
The sequences used in this study were submitted to GenBank
database and the accession number assigned for PKS and
NRPS gene sequences were KX306801–KX306815. Since some
sequences did not reach enough size to be submitted in this
database they are provided as SupplementaryMaterial (Annex I).
Secondary Metabolite Related In silico
Analysis of Planctomycete Genomes
The genomes of strains Rubripirellula obstinata LF1T (GenBank:
LWSK00000000), Roseimaritima ulvae UC8T (GenBank:
LWSJ00000000) and Planctomycetes strain FC18 (GenBank:
LWSI00000000) used in this study were previously curated and
annotated (unpublished results). The contigs were searched
for their genomic bioactive potential using antibiotics and
Secondary Metabolites Analysis Shell—antiSMASH 3.0 (Weber
et al., 2015) and NaPDoS annotation pipelines. The antiSMASH
analysis retrieved information of the biosynthetic clusters and
of biosynthetic, transport, and regulatory genes present in
the submitted genomes by gathering data of several in silico
secondary metabolite analyses tools. The NaPDoS tool was used
as referred above but using the Genome or metagenome contigs
(DNA) option. These two tools were used as a complement and
for data confirmation.
Antimicrobial Screenings
The screening of antimicrobial activity was performed in 35
planctomycetes (Table 1). Actively growing strains were initially
pre-cultured in M600 medium, at 25◦C, 220 r.p.m. for 2 days.
Each planctomycete was then incubated in M600 and M607
media (Lage and Bondoso, 2011) for 7 days, at 25◦C and 220
r.p.m. Each culture was then used to prepare four types of
bacterial extracts: 1 aqueous and 3 organic. The organic extracts,
for which a mixture of acetone plus 10% DMSO was used,
were obtained from culture broth (A/C), cell pellet (A/P), and
supernatant (A/S). Two milliliters of culture were used for the
A/C; another 2 mL of culture were centrifuged at 13,300 r.p.m.
for 5min and the supernatant (A/S) and pellet (A/P) collected.
To these three samples, 2ml of the solvent mixture were added.
These mixtures were incubated for 1 h under continuous shaking
and 2mL of the upper phase (organic) were removed to a new
tube and dried to half volume (twice concentrated). To the A/P
extracts, sterilized distilled water was added up to 1mL. To
obtain the aqueous supernatant extract (F), 2mL of culture were
centrifuged at 13,300 r.p.m. for 5min and the supernatant filter
sterilized through a 0.22 µm (Graça et al., 2015).
The target microorganisms used were grown overnight in
10mL of Luria Broth (LB) medium, at 37◦C and 220 r.p.m.
Cultures absorbance was measured at 600 nm and the cell
concentration adjusted to 2.5× 105 CFU/mL.
The extracts were assayed in 96 well-plates in triplicates three
times. Ninety microliter of each target culture were incubated
with 10 µL of each extract. The cultures were also incubated with
10 µL of the respective positive control: amphotericin B (0.19,
0.39, 0.78, and 1.56 µg.mL−1) against C. albicans, rifampicin
(62.5, 125, 250, and 500 mg.mL−1) against E. coli and P.
aeruginosa and chloramphenicol (3.75, 7.5, 15, and 30 µg.mL−1)
against B. subtilis and S. aureus. LB medium (100 µL) was used
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as negative control and 100 µL of the target cultures were used to
control the normal growth of the strains, both done in triplicate.
To ensure that neither the solvent mixture (acetone+DMSO)
nor the media induced inhibition of the cultures, 10 µL of each
condition was assayed with 90 µL of culture of each target strain
as controls. The inoculated plates were incubated at 37◦C and 220
r.p.m for 24 h. Initial and final absorbance measurements were
performed at 600 nm in a Multiskan GO plate reader (Thermo
Scientific) and analyses of the assays were carried out as described
in Graça et al. (2015). Extracts were only considered bioactive
when inhibitory values above 20% were obtained in two or more
assays showing, thus, consistency in the results.
RESULTS
The genomic potential of Planctomycetes to produce bioactive
compounds was assessed by amplification and sequencing of
PKS-I and NRPS genes and analysis in silico of tree genomes
(UC8, LF1, and FC18). Furthermore, screening assays were
performed in order to assess the production of antimicrobial
molecules.
PKS-I and NRPS Genes, Molecular, and In
silico Analysis
The search for the conserved motifs of the ketosynthase of the
PKS-I genes and core motif V of NRPS genes was performed
in 40 planctomycetes of 10 different taxa (Table 1; Figure S1).
Amplicons with several sizes were obtained from 38 strains
and bands extracted, DNA purified and sequenced. Only 24
strains were amplified for the expected product size (750 bp)
and 10 for other product sizes with the PKS-I primers. With
the NRPS primers, 17 planctomycetes amplified for the expected
product size (1000 bp) and five for other product sizes (Table 1).
Since these genes are understudied in Planctomycetes, amplicons
of unexpected sizes were also sequenced. It was only possible
to retrieve sequences from 18 amplicons. Seven out of the
11 amplicons with 750 bp and 2 amplicons with 600 bp
amplified with PKS-I primers confirmed the presence of the
ketosynthase gene in the planctomycetes. Two ketosynthase
genes were confirmed with the sequencing of NRPS amplicons
of 600 bp. Two amplicons of PKS-I genes with 750 bp were
found with potential to codify for a DUF1501 domain-containing
protein (FC24 and FC25), one for a putative membrane protein
(LF2) and another for a Rhodopirellula dipeptidyl peptidase
IV (OJF1). Concerning the NRPS amplification, only three
amplicons provided sequences confirming the presence of NRPS
modules (UC13, OJF1, and UC9). The Blast2go tool analysis of
the sequenced amplicons confirmed the results obtained in the
previous step using Blast in NCBI database (Table S1).
The phylogenetic tree using the amino acids corresponding
to the amplified PKS-I and the NRPS sequences revealed that
the PKS-I clustered together but were separated from the NRPS
with the exception of R. ulvae UF4.2 PKS-I which may be a
hybrid PKSI-NRPS (Figure 1). The PKS-I from two strains of
R. baltica clustered together as well as those of Rhodopirellula
lusitana. When considering the site sampling, phylogeny
(Figure S1), or macroalgal host-origin of the planctomycetes
analyzed (Lage and Bondoso, 2011), no correlation could be
obtained.
NaPDoS analysis showed that 10 of the amplified genes
encoded for modular KS and have somewhat similarity
with known secondary metabolite pathways involved in the
production of antitumor (UC49.1, UC8, and Rb), antibiotic (Gr7
and CcC8), antifungal (Gr7), quinol inhibitor (FF15, UF4.2,
UF3, and UC38), and toxins (FC9.2) (Table 1). Regarding NRPS
genes, NaPDoS in silico analysis showed a codification of C
domain with potential production of a toxin for OJF1 and a
DCL domain with potential production of bacitracin for UC9.
Since the percentage of similarity of the sequences obtained
using the NaPDoS is less than 80%, the prediction had to
be confirmed by blastnr. Furthermore, R. ulvae strains most
probably have uncharacterized biosynthetic gene clusters since
similarities lower than 85% were obtained with blastnr. In
fact, comparing the different analyses in silico performed, all
the strains belonging to the taxa R. ulvae (UC8, UF3, and
UF4.2) showed the presence of a PKS-I gene cluster not yet
characterized being the highest percentage of similarity of 71% in
strain UF4.2.
Secondary Metabolite Related In silico
Analysis of UC8, FC18, and LF1 Genomes
Nowadays, several are the tools available to search for
biosynthetic clusters, which are able to predict and provide
information on the genomic potential for the production of
bioactive compounds. In this work, antiSMASH, and NaPDoS
tools were used. The antiSMASH analysis showed that LF1 was
the one with higher number of biosynthetic clusters (9), followed
by UC8 (8), and FC18 (5; Figure 2). UC8 is the only strain that
possesses PKS-I clusters and LF1 the only one that possesses a
resorcinol cluster.
However, a closer analysis of the clusters related to secondary
metabolites revealed that UC8 is the strain with higher number
of biosynthetic genes (43), followed by LF1 (35), and FC18 (16;
Figure 3). The genes codifying for glycosyl transferase group
I, AMP-dependent synthethase, and ligase, terpene-cyclase,
polyprenyl synthase, and phytoene synthase are shared by all the
strains. Additionally to these genes, UC8, and LF1 are the strains
that sharemore genes (7), while UC8 and FC18 share 3 genes, and
LF1 and FC18 only one. Regarding unique biosynthetic genes,
UC8 is again the one that possesses the higher number with 18
genes, LF1 has 15 genes, and FC18 only 6 (Figure 3).
Although LF1 is the strain with the higher number of
biosynthetic clusters it does not have any kind of NRPS
gene (Figure 2) and contains the lowest number of regulatory
genes (Figure S2). LF1’s genome also contains in one cluster
a codification for an unknown biosynthetic pathway with a
regulatory gene similar to a LuxR response regulator and
another cluster coding for a terpene which has an AraC
family transcriptional regulator and two sigma-54 dependent
transcriptional regulators. One cluster of UC8 is a hybrid NRPS-
PKS-I which encodes for an epothilone biosynthetic gene and
holds a tetR family transcriptional regulator. A PKS-I cluster of
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FIGURE 1 | Maximum Likelihood tree showing the phylogenetic relationships determined from the PKS-I and NRPS gene amino acid translated
sequences of the 13 Planctomycetes sequenced amplicons. Equal input model was used. Bootstrap values were calculated based on 1000 resampling and are
shown beside nodes. In general PKS-I tend to group together as well as NRPS. Scale bar = 0.2 substitutions per 100 nucleotides.
FIGURE 2 | Numerical comparison of biosynthetic gene clusters present in genomes of strains LF1, UC8, and FC18 using antiSMASH analysis tool.
Strains LF1 and UC8 are comparatively the ones with a higher number of biosynthetic gene clusters. LF1 lacks NRPS genes.
UC8 holds a GntR family transcriptional regulator. There are
still five clusters with unknown attributed function and in all
the clusters there are still some uncharacterized biosynthetic,
transport and regulatory genes (Figure 2; Figure S2).
NaPDoS analysis of genomes secondary pathways confirmed
(1) gene similarities lower than 80%; (2) lack of any kind of
NRPS genes in LF1; (3) the presence of NRPS-PKS hybrids in
FC18 and UC8; and (4) that UC8 was the strain with the highest
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number of secondary metabolite genes (Figure 4). Hepatoxic
(FC18), anticancer (FC18 and UC8), antifungal (LF1, UC8,
and FC18), and antibiotic (LF1) activities were predicted by
NaPDoS.
Bioactivity Assays with Planctomycetes
The production of bioactive compounds by the planctomycetes
was only assessed in 35 strains due to growth limitation (Table 1).
Two culture media (M600 and M607) and four types of extracts
were assayed. Forty-three percent (15 strains) of the strains were
active against C. albicans and 54% (19 strains) against Bacillus
subtilis. Low activity was detected against the two strains of E. coli
and no activity was obtained against P. aeruginosa and S. aureus.
Figure 5 shows planctomycetes inhibition obtained against
C. albicans. The two more relevant extracts due to consistency
and level of inhibition were the aqueous supernatants of the
culture broths (F) in M600 from SM4 (average activity of 60%)
and from UC13 (average activity of 52%). The majority of the
bioactive extracts against C. albicans are from bacteria incubated
in medium M600 (83%). UC13 was the only strain that induced
inhibition with all extracts from M600. Three extracts were
bioactive for SM4: pellet (A/P), organic supernatant (A/S), and
aqueous supernatant (F). Only the supernatant extracts (A/S and
F) from the strains UC31, FC27 when incubated in M600 were
active. For R. baltica SH1T only extracts A/C and F in M600
were active. Strains FC3, FC9.2, UC36, and Gr7 only induced
bioactivity when the extracts were obtained from the pellet.
Strains UF2 and UF4.2 induced bioactivity with the aqueous
supernatant (F) when incubated in M600. However, when these
strains were incubated inM607 the bioactive extract was obtained
from the organic crude extract.
Regarding Bacillus subtilis (Figure 6), the strains with
consistent higher values of inhibitions were the organic
supernatants (A/S) in M600 of CcC8, UC31, and UF6 (average
activity of 52, 50, and 48%, respectively). However, the crude
extract of UF6 in M600 was the most inhibitory one with 66% of
average inhibition. The nine extracts with higher activity against
B. subtilis had approximately the same inhibitory activity as 7.5
µg/ml chloramphenicol (the third concentration of the MIC).
The extracts obtained from strains incubated in M600 (77%
strains) were more active than the ones incubated inM607. Sixty-
eight percent of the bioactive extracts were obtained from the
supernatant of the cultures broths [organic (A/S) or aqueous
(F)]. No pellet extract was active. While F extract in M600
obtained from FC9.2 was the least inhibitory (22% inhibition),
the value of inhibition raised to 35% when the supernatant was
extracted with acetone. The bioactive extracts of CcC6 in M607,
CcC8 in M607, FC27 in M607, SM4 in M600, and UF6 in
M600 were A/C and A/S which may indicate that the bioactive
molecules are possibly polar and secreted to the media. Also FF4,
UC13, and UC20 may produce bioactive molecules to the media
since all the bioactive extracts were obtained from A/S and F
extracts.
Ten strains were able to produce both antibiotic and
antifungal compounds: R. baltica SH1T; UC49.1; UC21; SM4;
UC13; UC17; UC31; UC36, Gr7; and FC9.2. In this work, 24
planctomycetes (69%) revealed bioactivity potential.
DISCUSSION
Nonribosomal peptides and polyketides are important groups
of secondary metabolites accounting for a significant portion of
known natural products (Walsh, 2004; Wang et al., 2014). In
an extensive genome mining of NRPS and PKS genes across
the three domains, Wang et al. (2014) observed that NRPS
and type I PKS clusters were more frequent in the phyla
Proteobacteria, Firmicutes, Actinobacteria, and Cyanobacteria.
Regarding Planctomycetes only a significant lower number
(seven) was analyzed of which five possessed PKS and hybrid
NRPS/PKS clusters. These results are in accordance with ours
since we only detected PKS and hybrids genes.
In our screening, although a high number of amplicons was
obtained for both type I PKS (66%) and NRPS (47%) genes,
only a reduced number could be confirmed to be PKS or NRPS
genes after sequencing. This may be due to the presence of
more than one KS and NRPS domain which may interfere
with the direct sequencing of the amplicons. Furthermore, four
non-specific amplifications (LF2, FC24, FC25, and UF2) were
also obtained with these primers which indicate the necessity
to confirm the amplifications obtained by sequencing. The
phylogenetic analyses of the retrieved PKS-I andNRPS sequences
also suggested that some planctomycetes that clustered together
(Figure 1; FC9.2, UC38, CcC8) may possess hybrid NRPS/PKS-I
modules because the amplified PKS-I sequences (Table 1) were
obtained with NRPS primers. The detection of PKS genes with
NRPS primers may also be a result of the low specificity of the
degenerate primers used in our work. Tambadou et al. (2014) also
obtained sequences without similarity to the A domain of NRPSs
in their study with marine mudflat bacteria.
The molecular analysis performed (Table 1) confirmed the
previous genome mining result obtained for R. baltica SH1T
which showed the presence of a type I PKS gene in this bacterium
(Jeske et al., 2013). Furthermore, the NaPDos tool predicted that
this gene, present in both R. baltica strains SH1 and UC49.1, may
encode for an epothilone. Gene structural similarity between the
two R. baltica is also evidenced by their phylogenetic relationship
(Figure 1). Although no absolute confirmation can be taken
regarding putative products, the analysis of the closest similar
products indicates an epothilone pathway for the two strains
of R. baltica. Epothilones are a new class of tubulin target
agents effective against human malignant disease (Cheng et al.,
2008). Originally epothilone was discovered from Sorangium
cellulosum, a myxobacterium isolated from the banks of Zambesi
River in Africa, and showed to be highly cytotoxic in vitro to the
human T-24 bladder carcinoma cell line (Gerth et al., 1996).
The presence of a polyketide synthase gene in Planctomyces
strain Gr7 is shared with Planctomyces brasiliensis (Jeske et al.,
2013) and these two planctomycetes have a 16 S rRNA gene
similarity of 100% (Lage and Bondoso, 2011) which demonstrates
their closeness. A predicted myxalamid pathway was foreseen
for the type I PKS gene sequenced from Planctomyces strain
Gr7. Myxalamids are antibiotics produced by themyxobacterium
Myxococcus xanthus and are known to block the respiration chain
at the site of complex I, i.e., NADH:ubiquinone oxidoreductase
(Gerth et al., 1983).
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FIGURE 3 | Comparison between the number of biosynthetic genes present in strains LF1, UC8, and FC18 genomes using antiSMASH analysis. UC8
followed by LF1 have more diverse biosynthetic genes. Common to the 3 strains are glycosyl transferase group I, AMP-dependent synthethase and ligase,
terpene-cyclase, polyprenyl synthase, and phytoene synthase genes.
FIGURE 4 | Pathway product prediction of the strains LF1, UC8, and FC18 genomes analysis using NaPDoS tool. Anticancer, antibiotic and antifungal are
the potential repertoire evidenced by the analyses of these genomes.
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FIGURE 5 | Average inhibition (percentage) of the positive extracts
against Candida albicans obtained from planctomycetes. Medium M600
was the one providing more extract bioactive against C. albicans and higher
inhibition values were obtained from the filtrate extract. M600 and
M607—medium of bacteria incubation; A/S—extract with acetone+DMSO
from the supernatant; A/P—extract with acetone+DMSO from the pellet;
A/C—extract with acetone+DMSO from the culture broth; F—extract from
filtrate of the supernatant.
R. lusitana strain UC38, R. ulvae UF3, and UF4.2 and an
uncharacterized new genus, strain FF15, revealed to amplify a
type I PKS gene with a predicted production of stigmatellin which
is an antibiotic produced by the myxobacterium Stigmatella
aurantiaca (Oettmeier et al., 1985). This antibiotic is a potent
electron transfer inhibitor of photosynthetic and respiratory
electron transports, inhibiting the quinol oxidation (Qo) site of
the cytochrome b6f complex of thylakoid membranes, of the
cytochrome bc1 complex (ubiquinol-cytochrome c reductase or
complex III) in mitochondria and of the bacterial photosynthetic
reaction center (Thierbach et al., 1984; Giangiacomo et al., 1987).
R. ulvae UC8 amplified also for a type I PKS gene that
potentially encodes for a myxothiazol which is an antifungal
antibiotic from the myxobacterium Myxococcus fulvus (Gerth
et al., 1980). Although its binding site is different of that
of stigmatellin, myxothiazol also is a competitive inhibitor
FIGURE 6 | Average inhibition (percentage) of the positive extracts
against Bacillus subtilis obtained from planctomycetes. Medium M600
was the one providing more extract bioactive against B. subitilis and higher
inhibition values were obtained from the organic extracts. M600 and
M607—medium of bacteria incubation; A/S—extract with acetone+DMSO
from the supernatant; A/P—extract with acetone+DMSO from the pellet;
A/C—extract with acetone+DMSO from the all culture broth; F—extract from
filtrate of the supernatant.
of ubiquinol. It binds at the quinol oxidation (Qo) site of
the mitochondrial cytochrome bc1 complex (Ouchane et al.,
2002). On the original screening of myxothiazol, Gerth et al.
(1980) observed growth inhibition of B. subtilis in plate culture
although no MIC concentration was determined. However, good
effectiveness of this antibiotic was detected against filamentous
fungi (Gerth et al., 1980). In our study no bioactivity was detected
by R. ulvae UC8 against neither C. albicans nor B. subtilis so
optimization of growth conditions is needed in order to attempt
the induction of such synthetic pathway.
Our results suggest that Planctomycetes potentially may
have several similar secondary metabolite pathways (epothilone,
stigmatellin, myxothiazol, myxamid) to Myxobacteria. This
bacterial group is known for their complex cell cycle, bioactive
potential, and large genomes (Schneiker et al., 2007; Huntley
et al., 2012). Also the gene synteny analysis revealed higher
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similarity with Myxobacteria PKS-I genes than with other
Planctomycetes (Figure S3).
Besides secondary pathways related to Myxobacteria, other
pathways are also present. Microcystin pathway is possibly
encoded by R. lusitana CcC8 and Rhodopirellula sp. FC9.2. The
synteny analysis of the PKS-I amplicon from FC9.2 revealed its
similarity to mcyE gene from Mycrocystis aeruginosa NIES 843
(Figure S3). Microcystins are a class of cyclic heptapeptide toxins
produced by several freshwater cyanobacteria namely members
of Microcystis, Planktothrix, Anabaena, Oscillatoria, and Nostoc
but recent evidence also suggest that they are also being produced
in the oceans by a number of cosmopolitan marine species
(Vareli et al., 2013). Microcystin biosynthesis gene cluster has a
highly conserved organization which includes NRPS, PKS, and
hybrid NRPS-PKS genes as has been characterized in the genus
Microcystis (Noguchi et al., 2009).
Regarding NRPS, UC9 demonstrated putative capacity for
the production of bacitracin, a mixture of cyclic peptides with
antibiotic properties through the inhibition of the cell wall
synthesis, produced by strains of Bacillus licheniformis (Stone
and Strominger, 1971). However, when gene synteny of the
NRPS was analyzed, closer similarity was obtained with genes
from Planctomycetes and with a different strain of Bacillus
(Figure S3) Furthermore, R. rubra OJF1 NRPS matches a HC-
toxin that is the host-selective toxin of the maize pathogen
(Walton, 2006).
Noteworthy is the low similarity of the predicted pathways
obtained in the analysis with NaPDoS tool databases which can
reveal the undiscovered pathways possessed by these strains. The
blastnr PKS-I and NRPS values obtained are indicative of new
secondary pathways, especially the PKS-I amplified from R. ulvae
strains which have the lowest similarity to their closest relatives.
Although the other planctomycetes strains used in this study
possess higher similarity values, their closest relatives do not have
their pathways characterized.
In the genome analysis of the three planctomycetes (LF1,
FC18, and UC8), besides PKS and NRPS clusters, a resorcinol
cluster was found in LF1. Resorcinol can be used as an antiseptic
and disinfectant in the treatment of chronic skin diseases such as
psoriasis, hidradenitis suppurativa, and eczema, as an oxidative
hair coloring product and as a food additive [SCCS (Scientific
Committee on Consumer Safety), 2010]. Furthermore, terpene
clusters are present in the three genomes. Terpenes comprehend
the largest class of plant natural products (Boutanaev et al., 2015)
but their bacterial origin has been known for many years and
terpene synthases are widely distributed in bacteria (Yamada
et al., 2015). Terpenes seem to be present in all planctomycetes
genomes (Jeske et al., 2013; Aghnatios et al., 2015) and terpenoid
synthases may be likely involved in carotenoid synthesis (Jeske
et al., 2013).
Strain LF1 has a transcriptional regulator of the AraC family
associated with the cluster coding for a terpene. These regulators
are widespread among bacteria and may be involved in the
stress responses to virulence (Frota et al., 2004). LF1 also has
extracytoplasmic function sigma factor (ECFs), two sigma-54
dependent transcription regulators. This particular ECF has been
regulated to various cellular processes like mobility, virulence,
biofilm formation, and nitrogen assimilation (Francke et al.,
2011). Although different ECFs were found, their presence in
planctomycetes has been previously described (Jogler et al.,
2012). Through the study of transcriptional regulators and
transporter genes found associated to the biosynthetic clusters,
the production of the secondary metabolites may be optimized as
well as their signaling induction.
The genomes analyzed sustain the relation between large
genomes and high number of biosynthetic clusters (Jeske et al.,
2013). However, FC18 is the strain with lower number of
biosynthetic clusters and genes which could be related to the fact
that it was the one that also provided the lowest information for
the annotation analysis. Also the absence of NRPS genes in LF1 is
in line with Jeske et al. (2013) where, summing up all the results,
only 38% of the planctomycetes possess any type of NRPS genes.
The secondary metabolite potential of our strains falls short of
that of Gemmata massiliana and Schlesneria paludicola which are
still the strains with the highest number of secondary metabolites
pathways (Aghnatios et al., 2015)
The products obtained by pathway prediction of the three
genomes using NaPDoS showed that these strains are potentially
able to produce a heat-stable antifungal factor (Figure 4). This
novel model of antifungal activity is encoded by a hybrid NRPS-
PKS that induces inhibition against a wide range of fungal species
(Yu et al., 2007). Furthermore, UC8 and FC18 showed genomic
potential to produce anticancer agents due to the potential
presence of epothilone and bleomycin pathways. Bleomycin
is a polyamine antibiotic produced by Streptomyces verticillus
known for its use in cancer treatment and also its toxicity to
bacteria and some tissues (Cohen and Josephine, 1976). Strain
LF1 possesses genomic potential for the production of antibiotics
with predicted pathways for rifamycin and alnumycin that can
show different bioactive properties. Ryfamycin is an important
antibiotic produced by several bacterial strains like Nocardia
RSP-3, Amycolatopsis mediterranei, marine Actinobacteria and
the marine sponge bacteria Salinispora and it is used to treat
tuberculosis leprosy and AIDS-related mycobacterial infections
(El-Tayeb et al., 2004; Kim et al., 2006; Hewavitharana et al.,
2007; Mahalaxmi et al., 2008). Alnumycin, initially discovered
from an endophytic Streptomyces sp., is an antibiotic with several
biological activities like inhibition of Gram positive bacteria and
human leukemia cells (Bieber et al., 1998).
Merging the information from the molecular and screening
assays we were able to confirm the genomic potential of nine
strains (SH1, UC49.1, FC9.2, UC9, CcC8, UC13, UF3, UF4.2,
Gr7). However, for 3 strains (UC38, UC8 and FF15), their
bioactivity is still undisclosed. This may be due to the specificity
of the produced compounds that may target different strains
or possess activities not screened for, such as antitumor or
antimalarial, or even to the need of different induction conditions
for the production of the compounds.
Stepping to the antimicrobial production, R. baltica showed
antibiotic and antifungal capacity. R. lusitana was the species
with the highest values of bioactivity against both C. albicans
and B. subtilis. Although R. rubra amplified for PKS-I and NRPS
genes no secondary metabolite pathway could be predicted with
NaPDoS and only bioactivity was detected against B. subtilis by
one strain (UC9). R. ulvae putatively possesses genes encoding
for the production of the antibiotics myxothiazol and stigmatellin
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and demonstrated high level of activity against C. albicans with
the filtrate extracts of UF2, UF3, and UF4.2, lower activity
with organic crude (A/C) extracts and no activity against B.
subitlis. The novel genus of strain FF15 showed putative synthetic
capacity for the production of stigmatellin but no bioactivity
could be detected. P. brasiliensis Gr7 demonstrated a great
antimicrobial capacity and the genomic potential production of
myxalamid.
Regarding the bioactivity screening, while some pellet extracts
were bioactive against C. albicans, none was active against B.
subtilis showing that the antifungal compounds were released to
the external medium. This is reinforced by the fact that most
of the bioactive extracts were obtained from the supernatants
(F). The fact that the number of bioactive supernatant extracts
obtained with acetone is lower than the aqueous ones can be
explained by low affinity of the molecules with the organic
solvent used. Occasionally, the pellet and supernatant extracts
obtained from a strain were both active while the crude was not,
suggesting, thus, an effect among the molecules extracted. This
effect may be due to interference with binding sites or counter
active actions of the molecules (Jia et al., 2009).
Bioactivity against C. albicans and B. subtilis was mainly
obtained when the planctomycetes were grown in M600
(respectively, 83 and 77% of the extracts), which is, comparatively
to M607, a medium with four fold yeast extract, peptone
and glucose. M600 appears to be the best medium for
bioactivity screenings of planctomycetes. It seems to favor their
antimicrobial production due to the favorable higher organic
medium conditions and/or the higher biomass yield (absorbance
measurements obtained when the bacteria were grown with
M600 were in general twice higher than the ones obtained
when incubated with M607—data not shown). These favor the
growth of fast growing heterotrophs which compete against
slower growing microorganisms like planctomycetes (doubling
times of several hours to days). The complexity of species and
interactions in biofilms impose the development of survival
strategies for their members. Moreover, all strains were isolated
from the surface of macroalgae, where they are subjected
to high levels of released polysaccharides and various forms
of environmental stresses like abrupt and broad changes in
salinity and temperature, high light intensities, and pollution.
As antimicrobials production was higher under higher organic
medium conditions, we postulate that high levels of organic
carbon may favorably trigger the production of antimicrobials
by planctomycetes, a plus for bacteria fighting for their presence
in biofilms. Several compounds, mainly polysaccharides, released
by macroalgae were identified as potential triggers for secondary
metabolite production (Jeske et al., 2013). In vitro antibiotics
production is commonly favored by starvation conditions which
are opposite to the hypothesis here formulated. However, we do
not know antibiotics role in the natural environment and how
they favor the producing organisms, but it is believed that they
control other microbes competing with their neighbors for space
and resources (Clardy et al., 2009; Hibbing et al., 2010).
Our results provide diverse and consistent evidence of
secondary metabolite production by several planctomycetes with
the production of putative novel metabolites of biotechnological
interest. Furthermore, the study of planctomycetes compounds
that are already known is of the utmost importance as
they may have different properties, namely regarding side
effects. The presence of genes related to bioactive pathways
or bioactivity production in all strains here studied seem to
be indicative of their potential ability to fight against their
competitor in the biofilm of macroalgae. The analysis of the
three genomes (FC18, LF1, and UC8) also revealed that these
strains possess a great potential to cope with environmental stress
(unpublished results). We should emphasize that this is the first
study reporting a high percentage of Planctomycetes extracts
with a great antibiotic and antifungal activity against Bacillus
subtilis and C. albicans. Further, studies into the secondary
molecules production by these scarcely studied bacteria open
the door to new promising and challenging biotechnological
studies.
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Annex 1 | PKS-I sequences not used in the phylogenetic tree because of
their small bp size and not submitted to GenBank database.
Table S1 | Results of the in silico analysis performed with the Blast2go
tool. These results confirm the ones obtained manually by search with Blastnr in
GenBank database.
Figure S1 | Phylogenetic 16 S rDNA tree generated by maximum-likelihood
analysis based in General Time Reversible model and Gamma distributed
with Invariant sites (G+I) indicating the relationship of the Planctomycetes
used in this work. Bar—0.05 substitutions per 1000 nucleotides.
Figure S2 | Number and description of transport and regulatory genes
present in strains LF1, UC8, and FC18 genomes reported by antiSMASH
analysis. UC8 is the strain with higher number of regulatory genes.
Frontiers in Microbiology | www.frontiersin.org 14 August 2016 | Volume 7 | Article 1241
Graça et al. Planctomycetes and Bioactivity
Figure S3 | Result of the synteny analysis of Planctomycetes PKS and
NRPS amplicons sequences with the closest strains as matched in
NaPDoS. All the strains were also searched against Planctomycetales group for
synteny. Only the results with higher similarity are shown.
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